Table 1 Patient demographics and disease
Patient | Primary tumor | Resected metastatic site for generation of vaccine | Time from initial diagnosis of disease to vaccine treatment (wks) | Time from diagnosis of stage IV disease to vaccine treatment (wks) | Number of previous surgical treatments for disease | Previous chemotherapy regimens |
|---|---|---|---|---|---|---|
1 | Colon | Liver | 30 | 21 | 2 | FOLFOX FOLFIRI Bevacizumab Capecitabine |
2 | Colon | Peritoneum, Liver | 161 | 161 | 4 | XELOX XELIRI Bevacizumab |
3 | Colon | Peritoneum | 119 | 119 | 2 | FOLFOX FOLFIRI Bevacizumab |
4 | Rectal | Peritoneum, Liver, Lymph Nodes | 374 | 282 | 6 | FOLFOX FOLFIRI Cetuximab Capecitabine |
5 | Colon | Peritoneum, Colon | 161 | 161 | 3 | FOLFOX FOLFIRI Bevacizumab |
6 | Colon | Peritoneum | 152 | 152 | 3 | FOLFOX FOLFIRI Bevacizumab Capecitabine |
7 | Colon | Pancreas, Peritoneum | 208 | 208 | 5 | FOLFOX FOLFIRI Cetuximab Bevacizumab Capecitabine |
8 | Rectal | Peritoneum, Small Bowel, Lymph Nodes | 344 | 150 | 4 | FOLFOX FOLFIRI Capecitabine |
9 | Rectal | Peritoneum, Liver | 163 | 141 | 3 | FOLFOX FOLFIRI Bevacizumab |